Therefore, blockade of the PD-1/PD-L1 signaling pathway by using specific antibodies to PD-1, such as nivolumab, yielded remarkable clinical responses in metastatic melanoma [9], non-small cell lung cell cancer [18], and renal cell carcinoma [19]. The gene discussed is PDCD1; the disease is metastatic melanoma.